Aristides Capital’s Cymabay Therapeutics CBAY Stock Holding History

Aristides Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-104,651	Closed	-$205K	–	263
2019 Q4	$205K	Buy	+104,651	New	+$393K	0.16%	153

Other funds holding CBAY

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aristides Capital's CBAY Position: Q1 2020 in Review

Aristides Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2020, closing a stake of 104,651 shares — an estimated $205K sold.

Aristides Capital first reported a position in CBAY in Q4 2019 and held it in 1 quarter. The position peaked at $205K in Q4 2019. 102 funds tracked by Wall St. Rank hold CBAY as of Q1 2020.

Aristides Capital reported no remaining Cymabay Therapeutics position as of Q1 2020 after selling out during the quarter.
Aristides Capital sold 104,651 Cymabay Therapeutics shares in Q1 2020, an estimated $205K.
Aristides Capital first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 1 quarter.
Aristides Capital's Cymabay Therapeutics position peaked at $205K in Q4 2019.
102 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.